Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food ...
Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.
Dr Nicholas Silvestri shares AAN 2025 highlights, including anticipated presentations, quick takeaways, and insights on the ...
GMA Network on MSN3d
Sunshine Cruz diagnosed with Myasthenia Gravis autoimmune diseaseSunshine Cruz shared that she has been diagnosed with an autoimmune disease, just a few days after walking in the Bench Body ...
Philstar Life on MSN3d
EXPLAINER: What is myasthenia gravis?Sunshine Cruz recently revealed that she’s battling an autoimmune disease called myasthenia gravis. In an Instagram post, the ...
A few days after walking at the Bench Body of Work fashion show, Sunshine Cruz revealed that she has been diagnosed with an autoimmune disease.
Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...
Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...
Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and while H.C. Wainwright analyst Douglas Tsao was ...
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...
The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback